Cocrystal Pharma

COCPPhase 2

Cocrystal Pharma is focused on discovering and developing first- and best-in-class antiviral drugs that target the viral replication machinery. The company's unique technology platform, guided by Nobel laureate Dr. Roger Kornberg, enables the efficient design of inhibitors against proteases and polymerases. With multiple programs advancing through clinical trials, including oral and inhaled candidates for influenza and a dual coronavirus-norovirus protease inhibitor, Cocrystal aims to address significant unmet needs in antiviral treatment with drugs designed to be safe, convenient, and resistance-resistant.

Market Cap

$645.0M

Focus

Small Molecules

COCP · Stock Price

USD 46.80169.20 (-78.33%)

Historical price data

AI Company Overview

Technology Platform

A structure-based drug discovery platform utilizing X-ray crystallography and Nobel Prize-winning expertise to design small-molecule inhibitors that target viral replication enzymes like proteases and polymerases.

Pipeline Snapshot

5 drugs in pipeline

Drug	Indication	Stage
CDI-31244 + SOF/VEL	Chronic Hepatitis C	Phase 2
CDI-988 + Placebo	Norovirus	Phase 1/2
CDI-31244 + Placebo	Hepatitis C	Phase 1
CC-42344 + Placebo	Influenza A	Phase 1
CDI-988 + Placebo	Healthy Volunteers	Phase 1

Funding History

Total raised: $57M

PIPE$20MUndisclosedSep 15, 2020

IPO$12MUndisclosedFeb 15, 2018

Series B$15MUndisclosedJun 15, 2015

Series A$10MUndisclosedJan 15, 2014

Opportunities

Significant opportunities exist in the large, underserved norovirus market where no approved antivirals exist.

The broad-spectrum potential of its protease inhibitors against multiple coronaviruses and the development of a convenient inhaled prophylactic for influenza represent additional high-value pathways for growth and differentiation.

Risk Factors

Key risks include clinical trial failures, the constant need for capital raising in a volatile market, intense competition from larger pharmaceutical companies in the antiviral space, and the potential for viral resistance to emerge against its novel mechanisms of action.

Competitive Landscape

Cocrystal faces competition from large pharma with approved influenza/coronavirus drugs (e.g., Roche, Pfizer, Merck) and other biotechs. Its primary competitive edge is its structure-based platform, which may yield drugs with better resistance profiles, and its focus on niche, high-unmet-need areas like norovirus where it could be a first mover.